Vivek Y. Reddy

Stories

Focal pulsed field ablation shows durable vein isolation in first-in-human trial

As of September 2026: Published peer-reviewed results; continues clinical development

Catheter ablation for atrial fibrillation has long forced a choice between flexible point-by-point radiofrequency and fast single-shot balloons. Field Medical's system tries to give both: a focal catheter that delivers the entire ablation pulse in under 200 milliseconds, eliminating the need for prolonged stable contact. Twelve-month results from its first-in-human trial, published Sunday in JACC: Clinical Electrophysiology, show 94.2% per-vein durable isolation with the optimized waveform.

Updated Sep 20

Wearable neuromodulation cuts recurrent atrial fibrillation events after ablation in pilot trial

New Capabilities

As of September 2026: Lead investigator of NeuroPulse pilot and prior ADVENT trial

Roughly one in four patients who get atrial fibrillation ablation sees the arrhythmia return within a year. StimCardio Medical tested a wrist-worn device designed to change that, and the pilot results show it cut recurrent arrhythmia events by 57%.

Updated Sep 20

Notable Quotes

“Field PULSE demonstrates the feasibility of truly instantaneous focal PFA” — Vivek Reddy

from Focal pulsed field ablation shows durable vein isolation in first-in-human trial · Updated Sep 20

"The question is not whether ablation works. It clearly does. The question is how we continue to improve outcomes for patients who experience recurrent arrhythmia despite increasingly advanced ablation technologies."

from Wearable neuromodulation cuts recurrent atrial fibrillation events after ablation in pilot trial · Updated Sep 20